Send to

Choose Destination
Breast Dis. 2004;20:33-42.

Immunobiology of her-2/neu transgenic mice.

Author information

Aging Research Center, University G. d'Annunzio Foundation, Chieti, Italy.


Development of the mammary gland is controlled by hormones and many other growth factors. Hyperplasia and neoplasia are thus a likely consequence of alterations in their number and type, or the number and function of their receptors. p185neu, a member of the epidermal growth factor family, is coded by the ErbB-2 oncogene. It is expressed in the normal human breast, but overexpressed and associated with a poor prognosis in 15-30% of breast tumours. Employment of ErbB-2 sequences as vaccinal antigens to induce an immune rejection of such tumours is being investigated in several transgenic animal models. One of the most aggressive models of mammary p185neu-dependent carcinogenesis is that of BALB-neuT mice, which are transgenic for the rat transforming Her-2/neu oncogene (a homologue of the human ErbB-2 oncogene). The progression of their early neoplastic lesions can be prevented with both cellular and DNA vaccines coadjuvated by antiangiogenic and immunostimulatory molecules. This suggests that induction of a specific immune reaction against a tumor target antigen may provide a way of preventing the onset of tumours in subjects with a high genetic risk of developing cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center